Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Celldex Therapeutics (CLDX) Operating Expenses (2016 - 2025)

Celldex Therapeutics (CLDX) has 16 years of Operating Expenses data on record, last reported at $87.3 million in Q4 2025.

  • For Q4 2025, Operating Expenses rose 52.57% year-over-year to $87.3 million; the TTM value through Dec 2025 reached $288.9 million, up 42.96%, while the annual FY2025 figure was $288.9 million, 42.96% up from the prior year.
  • Operating Expenses reached $87.3 million in Q4 2025 per CLDX's latest filing, up from $73.6 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $87.3 million in Q4 2025 and bottomed at $16.9 million in Q2 2021.
  • Average Operating Expenses over 5 years is $42.3 million, with a median of $38.7 million recorded in 2022.
  • Peak YoY movement for Operating Expenses: dropped 27.63% in 2021, then surged 116.07% in 2022.
  • A 5-year view of Operating Expenses shows it stood at $20.7 million in 2021, then soared by 42.68% to $29.5 million in 2022, then skyrocketed by 75.46% to $51.8 million in 2023, then increased by 10.52% to $57.2 million in 2024, then surged by 52.57% to $87.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $87.3 million in Q4 2025, $73.6 million in Q3 2025, and $64.6 million in Q2 2025.